AusperBio

United States · Biotech

Develops oligonucleotide therapeutics targeting chronic hepatitis B

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series C$120MCDH Investments — Role not disclosedHanKang Capital — Role not disclosedInnoPinnacle Fund — Role not disclosedQiming Venture Partners — Role not disclosedRA Capital Management — Role not disclosedSherpa Capital — Role not disclosedYuanBio Venture Capital — Role not disclosed
Sourcesausperbio.com ↗